REGULATION OF CELL GROWTH BY THE WILMS TUMOR GENE
Wilms 肿瘤基因对细胞生长的调节
基本信息
- 批准号:6173166
- 负责人:
- 金额:$ 12.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-07-01 至 2003-06-30
- 项目状态:已结题
- 来源:
- 关键词:3T3 cells Wilms' tumor athymic mouse cell differentiation cell growth regulation cell line developmental genetics gene expression gene interaction genetic promoter element growth inhibitors immunoprecipitation in situ hybridization neoplasm /cancer genetics neoplastic cell neoplastic transformation northern blottings protein structure function regulatory gene retinoblastoma protein transcription factor tumor suppressor genes tumor suppressor proteins
项目摘要
DESCRIPTION: (Adapted from investigator's abstract) The Wilms' tumor
suppressor gene, wt1, encodes a zinc finger transcription factor, WT1. A
number of mutations to the wt1 gene have been identified in subsets of Wilms
tumor, mesothelioma, ovarian tumor and acute myeloid leukemia, suggesting
that dysfunction of WT1 may be important in many tumors. However,
effectively nothing is known about the endogenous genes regulated by WT1,
and thus the signaling pathways triggered by WT1 and how mutated WT1
influences these pathways to result in Wilms' tumor remain to be discovered.
The long-term objective of the investigator's research is to characterize
the normal functions of WT1 during development and the dysfunctions of
mutated WT1 that lead to the genesis of Wilms' tumor. The investigators
recently cloned a gene whose expression is over tenfold greater in cells
expressing WT1 than in cells with undetectable levels of WT1. The gene was
identified as retinoblastoma (Rb) suppressor associated protein (AP)
(RbAp46), a nuclear protein that physically interacts with Rb. The
investigators have recently cloned and expressed the full-length cDNA of
RbAp46, and analyzed its effect on tumor cells. Remarkably, expression of
exogenous RbAp46 suppressed growth in four out of four tumor cell lines,
suggesting that RbAp46 itself has growth inhibitory activity. The
investigators now plan to establish the positive correlation between the
levels of WT1 and RbAp46 expression in different tumor cells and in mouse
tissues from different stages of development using Northern and in situ
hybridization analysis. They plan to analyze the promoter region of RbAp46
to determine whether WT1 directly regulates the expression of RbAp46. They
plan to explore the possible roles of RbAp46 as a mediator of WT1 function
by expressing exogenous RbAp46 or by down-regulating RbAp46 in cells. The
investigators plan to probe the mechanisms by which RbAp46 functions as a
growth inhibitor by analyzing its impact on the cell cycle and its influence
on the ras signaling pathway. The investigators plan to perform structure
and function analysis to identify the domain(s) of RbAp46 required for its
function. The investigators plan to identify the proteins which interact
with RbAp46 by co-immunoprecipitation and an in vivo GST capture assay and,
if necessary, by a yeast two-hybrid strategy. It is hoped that these
studies will lay the foundation of therapeutic intervention for the Wilms'
tumor and other tumors as well.
描述:(改编自研究者的摘要)威尔姆斯氏瘤
抑制基因 wt1 编码锌指转录因子 WT1。 一个
已在 Wilms 子集中鉴定出 wt1 基因的突变数量
肿瘤、间皮瘤、卵巢肿瘤和急性髓系白血病,提示
WT1 的功能障碍可能在许多肿瘤中很重要。 然而,
实际上,人们对 WT1 调节的内源基因一无所知,
以及 WT1 触发的信号通路以及 WT1 是如何突变的
影响这些途径导致维尔姆斯氏瘤的因素仍有待发现。
研究者研究的长期目标是表征
WT1在发育过程中的正常功能和功能障碍
WT1 突变导致肾母细胞瘤的发生。 调查人员
最近克隆了一个基因,其在细胞中的表达量高出十倍以上
表达 WT1 的细胞与 WT1 水平不可检测的细胞相比。 该基因是
被鉴定为视网膜母细胞瘤 (Rb) 抑制相关蛋白 (AP)
(RbAp46),一种与 Rb 发生物理相互作用的核蛋白。这
研究人员最近克隆并表达了全长 cDNA
RbAp46,并分析了其对肿瘤细胞的作用。 值得注意的是,表达
外源性 RbAp46 抑制了四种肿瘤细胞系中四种的生长,
表明RbAp46本身具有生长抑制活性。 这
研究人员现在计划建立两者之间的正相关关系
不同肿瘤细胞和小鼠中 WT1 和 RbAp46 的表达水平
使用 Northern 和原位分析来自不同发育阶段的组织
杂交分析。 他们计划分析 RbAp46 的启动子区域
以确定WT1是否直接调节RbAp46的表达。 他们
计划探索 RbAp46 作为 WT1 功能中介者的可能作用
通过表达外源 RbAp46 或下调细胞中的 RbAp46。 这
研究人员计划探究 RbAp46 作为
通过分析生长抑制剂对细胞周期的影响及其影响
位于 ras 信号通路上。 研究人员计划进行结构
和功能分析以确定 RbAp46 所需的结构域
功能。 研究人员计划鉴定相互作用的蛋白质
通过免疫共沉淀和体内 GST 捕获测定与 RbAp46 结合,
如有必要,通过酵母二杂交策略。 希望这些
研究将为威尔姆斯氏症的治疗干预奠定基础
肿瘤和其他肿瘤也是如此。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ZHAO-YI WANG其他文献
ZHAO-YI WANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ZHAO-YI WANG', 18)}}的其他基金
Estrogen Signaling in Normal and Transformed Cell Growth
正常和转化细胞生长中的雌激素信号传导
- 批准号:
7583966 - 财政年份:2006
- 资助金额:
$ 12.11万 - 项目类别:
Estrogen Signaling in Normal and Transformed Cell Growth
正常和转化细胞生长中的雌激素信号传导
- 批准号:
7391742 - 财政年份:2006
- 资助金额:
$ 12.11万 - 项目类别:
Estrogen Signaling in Normal and Transformed Cell Growth
正常和转化细胞生长中的雌激素信号传导
- 批准号:
7104684 - 财政年份:2006
- 资助金额:
$ 12.11万 - 项目类别:
Estrogen Signaling in Normal and Transformed Cell Growth
正常和转化细胞生长中的雌激素信号传导
- 批准号:
7209790 - 财政年份:2006
- 资助金额:
$ 12.11万 - 项目类别:
RB ASSOCIATED PROTEIN 46 AND BREAST CANCER PROGRESSION
RB 相关蛋白 46 与乳腺癌进展
- 批准号:
6195801 - 财政年份:2000
- 资助金额:
$ 12.11万 - 项目类别:
RB ASSOCIATED PROTEIN 46 AND BREAST CANCER PROGRESSION
RB 相关蛋白 46 与乳腺癌进展
- 批准号:
6377691 - 财政年份:2000
- 资助金额:
$ 12.11万 - 项目类别:
RB ASSOCIATED PROTEIN 46 AND BREAST CANCER PROGRESSION
RB 相关蛋白 46 与乳腺癌进展
- 批准号:
6633588 - 财政年份:2000
- 资助金额:
$ 12.11万 - 项目类别:
RB ASSOCIATED PROTEIN 46 AND BREAST CANCER PROGRESSION
RB 相关蛋白 46 与乳腺癌进展
- 批准号:
6514300 - 财政年份:2000
- 资助金额:
$ 12.11万 - 项目类别:
RB ASSOCIATED PROTEIN 46 AND BREAST CANCER PROGRESSION
RB 相关蛋白 46 与乳腺癌进展
- 批准号:
6795924 - 财政年份:2000
- 资助金额:
$ 12.11万 - 项目类别:
REGULATION OF CELL GROWTH BY THE WILMS TUMOR GENE
Wilms 肿瘤基因对细胞生长的调节
- 批准号:
6376614 - 财政年份:1998
- 资助金额:
$ 12.11万 - 项目类别:
相似海外基金
Development of novel therapies for ENL-mutated Wilms tumor
ENL 突变肾母细胞瘤新疗法的开发
- 批准号:
22KK0119 - 财政年份:2022
- 资助金额:
$ 12.11万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (B))
Wilms tumor 1 (Wt1) mutation reveals mechanisms of cell lineage crosstalk in the developing kidney
肾母细胞瘤 1 (Wt1) 突变揭示了发育中肾脏中细胞谱系串扰的机制
- 批准号:
10524717 - 财政年份:2022
- 资助金额:
$ 12.11万 - 项目类别:
Wilms tumor 1 (Wt1) mutation reveals mechanisms of cell lineage crosstalk in the developing kidney
肾母细胞瘤 1 (Wt1) 突变揭示了发育中肾脏中细胞谱系串扰的机制
- 批准号:
10665776 - 财政年份:2022
- 资助金额:
$ 12.11万 - 项目类别:
Elucidating Oncogenic Mechanisms Underlying Wilms Tumor Using Kidney Organoids
使用肾脏类器官阐明肾母细胞瘤的致癌机制
- 批准号:
10324558 - 财政年份:2021
- 资助金额:
$ 12.11万 - 项目类别:
WT1 as an oncogene and therapeutic target in anaplastic Wilms tumor
WT1 作为间变性肾母细胞瘤的癌基因和治疗靶点
- 批准号:
10552546 - 财政年份:2021
- 资助金额:
$ 12.11万 - 项目类别:
WT1 as an oncogene and therapeutic target in anaplastic Wilms tumor
WT1 作为间变性肾母细胞瘤的癌基因和治疗靶点
- 批准号:
10320453 - 财政年份:2021
- 资助金额:
$ 12.11万 - 项目类别:
Elucidating Oncogenic Mechanisms Underlying Wilms Tumor Using Kidney Organoids
使用肾脏类器官阐明肾母细胞瘤的致癌机制
- 批准号:
10543184 - 财政年份:2021
- 资助金额:
$ 12.11万 - 项目类别:
Characterizing the pathogenesis and targeted therapeutics of Wilms' Tumor 1 (WT1) mutations in AML
描述 AML 中 Wilms 肿瘤 1 (WT1) 突变的发病机制和靶向治疗
- 批准号:
10451996 - 财政年份:2019
- 资助金额:
$ 12.11万 - 项目类别:
The study of combination immunotherapy of Wilms' Tumor 1 (WT1) peptide vaccine in pediatric brain tumor
维尔姆斯氏瘤1(WT1)肽疫苗联合免疫治疗小儿脑肿瘤的研究
- 批准号:
19K18390 - 财政年份:2019
- 资助金额:
$ 12.11万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Characterizing the pathogenesis and targeted therapeutics of Wilms' Tumor 1 (WT1) mutations in AML
描述 AML 中 Wilms 肿瘤 1 (WT1) 突变的发病机制和靶向治疗
- 批准号:
10459634 - 财政年份:2019
- 资助金额:
$ 12.11万 - 项目类别: